REYON Pharmaceutical Co., Ltd. (KRX:102460)

REYON Pharmaceutical Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	8,528	10,209	24,107	16,049	66,741	12,196
Short-Term Investments	-	-	-	20,000	30,380	32,900
Trading Asset Securities	36.69	6.05	134.02	19.83	327.64	371.8
Cash & Short-Term Investments	8,564	10,215	24,241	36,069	97,448	45,468
Cash Growth	33.32%	-57.86%	-32.79%	-62.99%	114.32%	-23.36%
Accounts Receivable	36,844	36,720	39,927	41,810	40,465	39,946
Other Receivables	243.05	442.44	50.98	238.02	384.38	3,768
Receivables	37,087	37,162	39,978	42,048	40,850	43,714
Inventory	36,217	41,991	35,176	30,109	26,432	28,438
Prepaid Expenses	109.92	28.03	229.57	28.53	32.51	33.16
Other Current Assets	0.03	47.67	188.61	751.89	41.89	120.34
Total Current Assets	81,978	89,443	99,813	109,006	164,804	117,774
Property, Plant & Equipment	365,994	384,397	368,342	340,568	281,156	170,971
Long-Term Investments	17,252	16,011	21,216	26,211	24,557	21,150
Other Intangible Assets	1,530	1,803	1,392	1,404	1,427	1,442
Long-Term Deferred Tax Assets	2,399	4,408	5,075	4,104	2,004	2,058
Long-Term Deferred Charges	2,800	2,800	2,800	2,800	2,800	2,800
Other Long-Term Assets	1,154	1,131	1,137	598.41	1,230	1,415
Total Assets	473,107	499,994	499,776	484,692	477,978	317,610
Accounts Payable	6,696	10,028	8,186	4,793	4,731	4,168
Accrued Expenses	3,334	3,513	3,776	3,646	2,253	1,793
Short-Term Debt	98,293	81,201	94,656	22,500	22,500	20,420
Current Portion of Long-Term Debt	12,000	8,000	6,000	-	-	-
Current Portion of Leases	889.4	1,458	1,610	2,254	1,911	2,571
Current Income Taxes Payable	-	-	852.4	733.48	426.48	297.61
Other Current Liabilities	14,550	31,336	10,522	14,025	15,682	19,504
Total Current Liabilities	135,763	135,537	125,602	47,951	47,503	48,754
Long-Term Debt	103,000	113,000	121,000	184,218	182,425	33,800
Long-Term Leases	82.45	392.9	1,788	1,231	478.19	2,644
Long-Term Deferred Tax Liabilities	-	65.84	12.95	-	7.09	-
Other Long-Term Liabilities	1,141	1,057	2,748	3,526	2,328	2,323
Total Liabilities	239,986	250,053	251,151	236,926	232,741	87,521
Common Stock	9,293	9,293	9,293	8,999	8,999	8,781
Additional Paid-In Capital	38,955	38,955	38,955	39,003	39,003	26,281
Retained Earnings	190,605	207,397	205,997	205,151	202,281	200,208
Treasury Stock	-5,079	-5,079	-5,079	-5,079	-5,079	-5,002
Comprehensive Income & Other	-653.15	-625.3	-541.75	-559.4	-217.03	-178.11
Total Common Equity	233,121	249,941	248,625	247,515	244,987	230,089
Shareholders' Equity	233,121	249,941	248,625	247,765	245,237	230,089
Total Liabilities & Equity	473,107	499,994	499,776	484,692	477,978	317,610
Total Debt	214,265	204,053	225,054	210,203	207,314	59,435
Net Cash (Debt)	-205,700	-193,838	-200,813	-174,134	-109,866	-13,967
Net Cash Per Share	-11173.34	-10568.57	-10948.85	-9538.14	-6200.33	-820.17
Filing Date Shares Outstanding	18.31	18.34	18.34	17.75	17.75	17.32
Total Common Shares Outstanding	18.31	18.34	18.34	18.25	17.75	17.67
Working Capital	-53,785	-46,093	-25,789	61,055	117,301	69,020
Book Value Per Share	12734.92	13627.46	13555.68	13560.43	13799.95	13023.92
Tangible Book Value	231,591	248,138	247,233	246,111	243,561	228,647
Tangible Book Value Per Share	12651.33	13529.15	13479.79	13483.51	13719.59	12942.27
Land	12,362	12,362	12,362	12,362	12,362	12,362
Buildings	209,537	209,537	12,712	12,712	12,712	12,712
Machinery	169,103	166,017	43,939	42,519	39,530	38,263
Construction In Progress	47,535	45,487	342,022	314,018	256,737	142,914

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.